Hello, this is Franco
Goytia from CASPR Biotech.
At CASPR we're developing a portable
device for molecular diagnostics as a
platform powered through CRISPR and
novel CRISPR cas enzymes that we've
discovered.
And we're most specifically applying
these right now for COVID diagnostics and
advancing at full speed in order to have
our solution deployed for professionals
to use in the very short term.
Going down to the lab,
where the magic happens.
Our protein purification team
brainstorming something here.
And now the lab, which
you can see here. We'll go
invade their space.
Currently there's not enough testing,
but also for many of the testing solutions
which are available, the process,
such as the RNA extraction process and
the reagents or equipment required for
that are also in shortage.
So, it's a system that
has suffered from key complications
throughout the pipeline of what is needed
for a diagnostic test to be performed.
So inside the lab,
we have our CRISPR team
working, doing validations, very
serious. And
our protein team working. Full speed.
So we integrate our own cas enzyme and
these technologies as a platform for
detection with lab on a paper and a
microfluidics device and, jointly,
we are automating the entire
CRISPR detection flow,
from sample to answer,
into a 60 minute procedure with
the device being the reusable part,
the size of a smartphone or smaller,
and our cartridges being the
input of what is to be detected.
In this case, cartridges
for COVID-19 detection.
We're already doing pilots with different
ministries of health and CDCs from
from around the world.
Both the public sector,
as well as private companies and private
laboratory networks and so forth are
also very interested in the accessibility
and precision that our technology
brings to decentralized diagnostics.
It's a critical time for the world.
There's a great need for
more tests to be available.
We're trying to do our part.
We're still some time out from having
our solution fully manufactured and fully
developed,
but we are doing as much as possible so
as to have it within not many months but
a short period of time. And we have Natti.
Dorey from our biomedical
engineering team.
Here we have some sample preparation
and validation team there,
with Carlos our project manager.
Serious faces. That's part of our team,
here in the IndieBio lab in San Francisco.
Others are working in our
lab in Buenas Aires. And yes,
we're fully committed
to making this happen.
